Gland Pharma Ltd
Gland Pharma Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #6 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Gland Pharma Ltd Q2 FY27 key numbers
- Revenue
- CDMO revenue: ₹8,227 million, up 31% YoY.
As stated in Gland Pharma Ltd's Q2 FY27 investor presentation · published 6 Nov 2026. Reported figures, not investment advice.
Based on Gland Pharma Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5). EBITDA for Q2 FY27: ₹4,804 million, a 53% year-on-year (YoY) increase from ₹3,139 million in Q2 FY26.
From Gland Pharma Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Gland Pharma's revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5).
- CDMO revenue: ₹8,227 million, up 31% YoY (Page 9).
- Critical Injectables revenue: ₹10,109 million, up 18% YoY (Page 9).
- US Market Total Revenue CDMO: ₹11,795 million, 37% YoY growth (Page 13).
- Europe Market Total Revenue CDMO: ₹3,710 million, 25% YoY growth (Page 14).
- India Market Total Revenue CDMO: ₹387 million, down 42% YoY (Page 17).
2 more points from Gland Pharma Ltd's call on revenue
Create a free account to keep reading this call
What happened to Gland Pharma's margins in Q2 FY27?
See what Gland Pharma Ltd said on profitability & margins — free account, 30 seconds.
What capex is Gland Pharma planning?
- Capital Expenditure (Capex) for 6M FY27 was ₹2,562 Mn, lower compared to previous years (₹3,938 Mn in FY25, ₹4,938 Mn in FY26) (Page 7).
- Technology transfer activities are progressing as planned for the CDMO partnership with a global pharmaceutical company, with additional dossiers added (Page 11).
- Strategic CDMO collaborations have led to secured manufacturing contracts for microspheres and respiratory products (Page 11).
- 15 products are in co-development expected to commercialize from FY29 (Page 11), indicating pipeline and capacity expansion efforts.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Gland Pharma raising money or cutting debt?
See what Gland Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Gland Pharma's order book?
See what Gland Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Gland Pharma Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.7K Cr, net profit ₹367 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gland Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Ipca Laboratories (Q2 FY27)
Volume-led growth in pain segment is around 8-9%, with price growth at 4-4.5%. Key concall takeaways from Ipca Laboratories Ltd's Q2 FY27 earnings call — and…
- OneSource Specialty Pharma (Q2 FY27)
. Key concall takeaways from OneSource Specialty Pharma Ltd's Q2 FY27 earnings call — and how it ranks against sector peers.
- Supriya Lifescience (Q2 FY27)
Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9). Key investor presentation takeaways from Supriya L
- Sai Life Sciences Ltd (Q2 FY27)
Revenue for Q2 FY27: ₹659 Cr, a 23% year-on-year (YoY) growth from ₹537 Cr in Q2 FY26 (Page 8, 30). Key investor presentation takeaways from Sai Life Sciences L
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gland Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gland Pharma Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5). EBITDA for Q2 FY27: ₹4,804 million, a 53% year-on-year (YoY) increase from ₹3,139 million in Q2 FY26.
What is Gland Pharma Ltd share price analysis?
Gland Pharma Ltd currently shows a neutral. The stock trades at a P/E of 45.3 with a market cap of ₹51,906 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma Ltd planning capital expenditure?
Capital Expenditure (Capex) for 6M FY27 was ₹2,562 Mn, lower compared to previous years (₹3,938 Mn in FY25, ₹4,938 Mn in FY26) (Page 7).
Keep Gland Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.